nach oben

European Journal of Nuclear Medicine and Molecular Imaging

Erschienen in:

14.08.2023 | Original Article

Total-body [⁶⁸ Ga]Ga-PSMA-11 PET/CT improves detection rate compared with conventional [⁶⁸ Ga]Ga-PSMA-11 PET/CT in patients with biochemical recurrent prostate cancer

verfasst von: Yining Wang, Zijun Chen, Yinjie Zhu, Haitao Zhao, Lianghua Li, Gang Huang, Wei Xue, Ruohua Chen, Jianjun Liu

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 13/2023

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The purpose of this study was to assess whether total-body [⁶⁸ Ga]Ga-PSMA-11 PET/CT could improve the detection rate compared with conventional [⁶⁸ Ga]Ga-PSMA-11 PET/CT in patients with biochemical recurrent prostate cancer.

Methods

Two hundred biochemical recurrent prostate cancer patients with similar clinicopathological characteristics were included, of whom 100 patients underwent early total-body [⁶⁸ Ga]Ga-PSMA-11 PET/CT and diuretic-delayed total-body [⁶⁸ Ga]Ga-PSMA-11 PET/CT, and the other 100 patients received early conventional [⁶⁸ Ga]Ga-PSMA-11 PET/CT and diuretic-delayed conventional [⁶⁸ Ga]Ga-PSMA-11 PET/CT. The detection rates of total-body [⁶⁸ Ga]Ga-PSMA-11 PET/CT and conventional [⁶⁸ Ga]Ga-PSMA-11 PET/CT were compared using a chi-square test and stratified analysis. The image quality of total-body [⁶⁸ Ga]Ga-PSMA PET/CT and conventional [⁶⁸ Ga]Ga-PSMA-11 PET/CT was compared based on subjective scoring and objective parameters. Subjective scoring was conducted from background noise and lesion prominence using a 5-point scale. Objective parameters were evaluated by SUVmax, SUVmean, the standard deviation (SD) of SUV, and the signal-to-noise ratio (SNR) of liver and gluteus maximus. The SUVmax of the recurrent lesions was also measured.

Results

The liver SD of the total-body [⁶⁸ Ga]Ga-PSMA-11 PET/CT was significantly lower than that of conventional [⁶⁸ Ga]Ga-PSMA-11 PET/CT, the SNR was significantly higher than that of conventional [⁶⁸ Ga]Ga-PSMA-11 PET/CT, and the subjective evaluation was significantly better than that of conventional [⁶⁸ Ga]Ga-PSMA-11 PET/CT. The detection rate of total-body [⁶⁸ Ga]Ga-PSMA PET/CT for biochemical recurrence of prostate cancer was significantly higher than that of conventional [⁶⁸ Ga]Ga-PSMA-11 PET/CT (91.0% vs. 74.0%, P = 0.003). Total-body [⁶⁸ Ga]Ga-PSMA-11 PET/CT had better detection efficiency for patients with a Gleason score ≤ 8 or PSA ≤ 2 ng/ml. The advantages of diuretic-delayed total-body [⁶⁸ Ga]Ga-PSMA-11 PET/CT were more obvious.

Conclusion

Total-body [⁶⁸ Ga]Ga-PSMA-11 PET/CT could significantly improve the detection rate compared with conventional [⁶⁸ Ga]Ga-PSMA-11 PET/CT in patients with biochemical recurrent prostate cancer.

Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022;72(1):7–33.CrossRefPubMed

Isbarn H, Wanner M, Salomon G, Steuber T, Schlomm T, Kollermann J. Long-term data on the survival of patients with prostate cancer treated with radical prostatectomy in the prostate-specific antigen era. BJU Int. 2010;106(1):37–43.CrossRefPubMed

Huo H, Shen S, He D, Liu B, Yang F. Head-to-head comparison of ⁶⁸Ga-PSMA-11 PET/CT and ⁶⁸Ga-PSMA-11 PET/MRI in the detection of biochemical recurrence of prostate cancer: summary of head-to-head comparison studies. Prostate Cancer Prostatic Dis. 2023;26(1):16–24.

Zhang X, Cherry SR, Xie Z, Shi H, Badawi RD, Qi J. Subsecond total-body imaging using ultrasensitive positron emission tomography. Proc Natl Acad Sci U S A. 2020;117(5):2265–7.CrossRefPubMedPubMedCentral

Badawi RD, Shi H, Hu P, et al. First human imaging studies with the EXPLORER total-body PET scanner. J Nucl Med. 2019;60(3):299–303.CrossRefPubMedPubMedCentral

Zhang X, Xie Z, Berg E, et al. Total-body dynamic reconstruction and parametric imaging on the uEXPLORER. J Nucl Med. 2020;61(2):285–91.CrossRefPubMedPubMedCentral

Cherry SR, Jones T, Karp JS, Qi J, Moses WW, Badawi RD. Total-body PET: maximizing sensitivity to create new opportunities for clinical research and patient care. J Nucl Med. 2018;59(1):3–12.CrossRefPubMedPubMedCentral

Zhang X, Zhou J, Cherry SR, Badawi RD, Qi J. Quantitative image reconstruction for total-body PET imaging using the 2-meter long EXPLORER scanner. Phys Med Biol. 2017;62(6):2465–85.CrossRefPubMedPubMedCentral

Tan H, Sui X, Yin H, et al. Total-body PET/CT using half-dose FDG and compared with conventional PET/CT using full-dose FDG in lung cancer. Eur J Nucl Med Mol Imaging. 2021;48(6):1966–75.CrossRefPubMed

10.

Zhao YM, Li YH, Chen T, et al. Image quality and lesion detectability in low-dose pediatric 18F-FDG scans using total-body PET/CT. Eur J Nucl Med Mol Imaging. 2021;48(11):3378–85.CrossRefPubMed

11.

Zhang YQ, Hu PC, Wu RZ, et al. The image quality, lesion detectability, and acquisition time of 18F-FDG total-body PET/CT in oncological patients. Eur J Nucl Med Mol Imaging. 2020;47(11):2507–15.CrossRefPubMed

12.

Fu F, Li X, Wu Y, et al. Total-body dynamic PET/CT of micro-metastatic lymph node in a patient with lung cancer. Eur J Nucl Med Mol Imaging. 2021;48(5):1678–9.CrossRefPubMed

13.

Eiber M, Herrmann K, Calais J, et al. Prostate cancer molecular imaging standardized evaluation (PROMISE): proposed miTNM classification for the interpretation of PSMA-ligand PET/CT. J Nucl Med. 2018;59(3):469–78.CrossRefPubMed

14.

van Sluis J, Boellaard R, Somasundaram A, et al. Image quality and semiquantitative measurements on the biograph vision PET/CT system: initial experiences and comparison with the biograph mCT. J Nucl Med. 2020;61(1):129–35.CrossRefPubMed

15.

Chen W, Liu L, Li Y, et al. Evaluation of pediatric malignancies using total-body PET/CT with half-dose [18F]-FDG. Eur J Nucl Med Mol Imaging. 2022;49(12):4145–55.CrossRefPubMed

16.

Van den Broeck T, van den Bergh RCN, Briers E, et al. Biochemical recurrence in prostate cancer: the European Association of Urology Prostate Cancer Guidelines Panel Recommendations. Eur Urol Focus. 2020;6(2):231–4.CrossRefPubMed

17.

Fendler WP, Eiber M, Beheshti M et al. PSMA PET/CT: joint EANM procedure guideline/SNMMI procedure standard for prostate cancer imaging 2.0. Eur J Nucl Med Mol Imaging. 2023;50(5):1466–1486.

18.

Hohberg M, Kobe C, Täger P, et al. Combined early and late ⁶⁸Ga-PSMA-HBED-CC PET scans improve lesion detectability in biochemical recurrence of prostate cancer with low PSA levels. Mol Imaging Biol. 2019;21:558–66.CrossRefPubMed

19.

Alberts I, Sachpekidis C, Gourni E, et al. Dynamic patterns of ⁶⁸Ga-PSMA-11 uptake in recurrent prostate cancer lesions. Eur J Nucl Med Mol Imaging. 2020;47(1):160–7.CrossRefPubMed

20.

Alberts I, Niklas-Hünermund J, Sachpekidis C, et al. Combination of forced diuresis with additional late imaging in ⁶⁸Ga-PSMA-11 PET/CT: effects on lesion visibility and radiotracer uptake. J Nucl Med. 2021;62(9):1252–7.CrossRefPubMed

21.

Kunikowska J, Pełka K, Tayara O, Królicki L. ⁶⁸Ga-PSMA-11 PET/CT in patients with biochemical recurrence of prostate cancer after primary treatment with curative intent-impact of delayed imaging. J Clin Med. 2022;11(12):3311.CrossRefPubMedPubMedCentral

22.

Rouvière O, Vitry T, Lyonnet D. Imaging of prostate cancer local recurrences: why and how? Eur Radiol. 2010;20:1254–66.CrossRefPubMed

23.

Daub Witherspoon ME, Pantel AR, Pryma DA, Karp JS. Total-body PET: a new paradigm for molecular imaging. Br J Radiol. 2022;95(1140):20220357.CrossRef

Titel: Total-body [68 Ga]Ga-PSMA-11 PET/CT improves detection rate compared with conventional [68 Ga]Ga-PSMA-11 PET/CT in patients with biochemical recurrent prostate cancer
verfasst von: Yining Wang
Zijun Chen
Yinjie Zhu
Haitao Zhao
Lianghua Li
Gang Huang
Wei Xue
Ruohua Chen
Jianjun Liu
Publikationsdatum: 14.08.2023
Verlag: Springer Berlin Heidelberg
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 13/2023
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-023-06355-5

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Total-body [⁶⁸ Ga]Ga-PSMA-11 PET/CT improves detection rate compared with conventional [⁶⁸ Ga]Ga-PSMA-11 PET/CT in patients with biochemical recurrent prostate cancer

Abstract

Purpose

Methods

Results

Conclusion

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 13/2023

Correction to: Highlights of the 35th EANM Annual Congress 2022, onsite edition in Barcelona, Spain: “FROM BARCELONA WITH LOVE”

Feasibility of [18F]fluoropivalate hybrid PET/MRI for imaging lower and higher grade glioma: a prospective first-in-patient pilot study

One stop non-invasive identification of culprit vessels and related ischemia in coronary artery bypass patient using combined 82Rubidium PET/coronary CT angiography

Impact of cardiac history and myocardial scar on increase of myocardial perfusion after revascularization

Correction to: Next‑generation PET/CT imaging in meningioma—first clinical experiences using the novel SSTR‑targeting peptide [18F]SiTATE

Comparing the clinical value of baseline [68 Ga]Ga-FAPI-04 PET/CT and [18F]F-FDG PET/CT in pancreatic ductal adenocarcinoma: additional prognostic value of the distal pancreatitis